US FDA grants final approval to Zydus’s Micafungin for injection

The United States Food and Drug Administration (FDA) has granted final approal to Zydus Lifesciences for marketing Micafungin for injection, 50 mg/vial and 100 mg/vial, single-dose vials, Zydus Lifesciences notified in a statement.

According to the statement, Micafungin for injection is indicated to treat variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem cell transplant. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India.